CytomX Therapeutics
CTMX
86 hedge funds and large institutions have $332M invested in CytomX Therapeutics in 2017 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 29 increasing their positions, 20 reducing their positions, and 3 closing their positions.
800% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 3
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
79% more capital invested
Capital invested by funds: $185M → $332M (+$146M)
45% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 20
26% more funds holding
Funds holding: 68 → 86 (+18)
6.08% more ownership
Funds ownership: 46.31% → 52.39% (+6.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$16.4M |
| 2 |
BlackRock
New York
|
+$13.2M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$10.5M |
| 4 |
PA
Perceptive Advisors
New York
|
+$7.99M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$3.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$17M |
| 2 |
VMI
VHCP Management II
New York
|
-$3.8M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$2.97M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.86M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$696K |
CTMX Hedge Fund Activity: Q1 2017 in Review
86 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q1 2017, worth a combined $332M — up 79% from $185M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new CTMX positions and 3 closed out — a net gain of 24 holders — while 29 added to existing stakes and 20 trimmed.
The largest buyer was BVF Inc, adding an estimated $16.4M. The largest seller was Putnam Investments, cutting an estimated $17M.
- 86 institutional investors held CytomX Therapeutics (CTMX) as of Q1 2017, up from 68 in Q4 2016.
- Funds reported $332M of CytomX Therapeutics stock for Q1 2017, up 79% quarter-over-quarter.
- 27 funds opened new CytomX Therapeutics positions in Q1 2017 and 3 closed out, a net change of +24 holders.
- The largest CytomX Therapeutics buyer in Q1 2017 was BVF Inc, an estimated $16.4M added.
- The largest CytomX Therapeutics seller in Q1 2017 was Putnam Investments, an estimated $17M sold.
Based on aggregated 13F filings for Q1 2017.